The 6-hydroxydopamine model: news from the past
- PMID: 18595767
- DOI: 10.1016/j.parkreldis.2008.04.015
The 6-hydroxydopamine model: news from the past
Abstract
The investigation of pathogenic and pathophysiological mechanisms of Parkinson's disease relies on experimental models reproducing, in the animal, the pathological and behavioural features of the disease. Despite the availability of innovative models, 6-hydroxydopamine (6-OHDA) remains the most widely used tool to induce a nigrostriatal lesion in the animal (rat). This is due to (1) the relatively low complexity and cost of the procedure, (2) the fact that the 6-OHDA-induced lesion is highly reproducible, and (3) the versatility of the procedure, which can yield varying degrees of nigrostriatal lesions that develop with different temporal profiles, depending on the site chosen for the toxin injection.
Similar articles
-
Characterization of the striatal 6-OHDA model of Parkinson's disease in wild type and alpha-synuclein-deleted mice.Exp Neurol. 2008 Mar;210(1):182-93. doi: 10.1016/j.expneurol.2007.10.012. Epub 2007 Nov 1. Exp Neurol. 2008. PMID: 18053987
-
The unilateral 6-OHDA rat model of Parkinson's disease revisited: an electromyographic and behavioural analysis.Eur J Neurosci. 2005 Aug;22(3):735-44. doi: 10.1111/j.1460-9568.2005.04238.x. Eur J Neurosci. 2005. PMID: 16101755
-
Time-course of nigrostriatal damage, basal ganglia metabolic changes and behavioural alterations following intrastriatal injection of 6-hydroxydopamine in the rat: new clues from an old model.Eur J Neurosci. 2007 Jan;25(2):397-405. doi: 10.1111/j.1460-9568.2006.05285.x. Eur J Neurosci. 2007. PMID: 17284180
-
The 6-hydroxydopamine model of Parkinson's disease.Neurotox Res. 2007 Apr;11(3-4):151-67. doi: 10.1007/BF03033565. Neurotox Res. 2007. PMID: 17449457 Review.
-
Role of receptor heterodimers in the development of L-dopa-induced dyskinesias in the 6-hydroxydopamine rat model of Parkinson's disease.Parkinsonism Relat Disord. 2008;14 Suppl 2:S159-64. doi: 10.1016/j.parkreldis.2008.04.022. Parkinsonism Relat Disord. 2008. PMID: 18638717 Review.
Cited by
-
Neuroprotection by silencing iNOS expression in a 6-OHDA model of Parkinson's disease.J Mol Neurosci. 2012 Sep;48(1):225-33. doi: 10.1007/s12031-012-9814-5. Epub 2012 May 26. J Mol Neurosci. 2012. PMID: 22638860
-
Subthalamic Deep Brain Stimulation Affects Plasma Corticosterone Concentration and Peripheral Immunity Changes in Rat Model of Parkinson's Disease.J Neuroimmune Pharmacol. 2021 Jun;16(2):454-469. doi: 10.1007/s11481-020-09934-7. Epub 2020 Jul 9. J Neuroimmune Pharmacol. 2021. PMID: 32648088 Free PMC article.
-
Alteration of colonic excitatory tachykininergic motility and enteric inflammation following dopaminergic nigrostriatal neurodegeneration.J Neuroinflammation. 2016 Jun 13;13(1):146. doi: 10.1186/s12974-016-0608-5. J Neuroinflammation. 2016. PMID: 27295950 Free PMC article.
-
The effects of prenatal methylmercury exposure on trace element and antioxidant levels in rats following 6-hydroxydopamine-induced neuronal insult.Metab Brain Dis. 2014 Jun;29(2):459-69. doi: 10.1007/s11011-013-9465-4. Epub 2013 Dec 17. Metab Brain Dis. 2014. PMID: 24338101
-
Adenosine A1 and A2A receptors are involved on guanosine protective effects against oxidative burst and mitochondrial dysfunction induced by 6-OHDA in striatal slices.Purinergic Signal. 2021 Jun;17(2):247-254. doi: 10.1007/s11302-021-09765-y. Epub 2021 Feb 6. Purinergic Signal. 2021. PMID: 33548045 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous